CeQur has raised $100 million in Series E financing to support the expansion of its Simplicity wearable mealtime insulin patch, a device designed to make insulin delivery easier for people with diabetes. The Switzerland-based company developed Simplicity as a wearable alternative to traditional insulin pens, allowing users to deliver mealtime insulin through a discreet patch system.
Related: Kalogon raises $5.75M to make sitting healthier for all
The funding comes as CeQur enters a major commercial growth phase. The company plans to use the investment to expand its commercial operations, strengthen relationships with healthcare providers and diabetes specialists, and increase access to its technology.
Simplicity has continued to advance through regulatory milestones. The device initially received FDA clearance and CE marking, and later gained approval for longer wear periods. The FDA recently cleared the system for up to seven days of continuous wear and approved a new 1-unit (1U) device option, reducing the burden of frequent mealtime insulin administration.
CeQur CEO Bradley Paddock highlighted the company’s readiness to scale, stating:
“We have the commercial infrastructure, new clinical evidence. and an exciting pipeline. Now we have the capital to accelerate our growth. CeQur Simplicity is ready to reach every patient and physician who wants to simplify their insulin delivery and improve their diabetes management.”
CFO Mike Rubino added that the financing reflects investor confidence in CeQur’s future:
“This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur’s growth trajectory.”
The Series E round represents a key step in CeQur’s strategy to expand the availability of Simplicity and advance its mission of making insulin management more convenient and accessible for patients.
